Study Comparing Length of Dual Anti-Platelet Therapy Using Aspirin and Clopidogrel or Prasugrel After New Generation Drug-Eluting Stents in Adults with Advanced Chronic Kidney Disease
Led by Yonsei University · Updated on 2026-01-21
900
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the best length of dual anti-platelet therapy using aspirin and either clopidogrel or prasugrel after placing new generation drug eluting stents in patients with advanced chronic kidney disease. This prospective, open-label, multicenter randomized clinical trial aims to compare clinical outcomes based on therapy duration in adults with chronic kidney disease stages IIIb to V. The study is led by Yonsei University and focuses on patients who have undergone percutaneous coronary intervention with these stents.
Participants receive one of two treatments dual anti-platelet therapy with aspirin 100 mg plus either clopidogrel 75 mg or prasugrel 10 mg daily for at least 6 months, or the same therapy for 3 months or less followed by clopidogrel or prasugrel alone. The study compares these two groups over one year, assessing outcomes related to cardiovascular events and bleeding risks.
During the study, participants are monitored for clinical events including net clinical adverse events, cardiovascular death, major adverse cardiovascular events, and bleeding complications over one year. Researchers will analyze data according to kidney disease stage, clinical presentation, and stent type. The total participation duration depends on follow-up assessments at regular intervals within the one-year period.
CONDITIONS
Brief Title
Appropriate Duration of Anti-Platelet straTegy in Patients With Advance Chronic Kidney Disease After New Generation Drug Eluting Stents (ADAPT-CKD)
Research Team
J
Jung-Sun Kim, MD, PhD, FESC
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Chronic renal failure stage IIIb, IV, or V (CKD-EPI eGFR <45 / <30 / <15 or dialysis)
Patients treated with a new generation drug eluting stent
Patients who signed consent form
You will not qualify if you...
Over 85 years old
Patients with high risk of bleeding including history of hemorrhagic stroke, recent stroke, dementia or central nervous system damage within 1 year, recent head trauma or brain surgery within 6 months, skull tumor, suspected aortic dissection, recent internal bleeding within 6 weeks, active bleeding or bleeding disorder, or recent major surgery, trauma or bleeding within 3 weeks
Patients who need oral anticoagulant
Pregnant women or women of childbearing age
Life expectancy less than 1 year
Patients with a history of intracranial bleeding
Moderate to severe hepatic impairment (Child-Pugh class B or C)
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Up to 6 months
Participants receive dual anti-platelet therapy with aspirin plus clopidogrel or prasugrel for either less than 3 months or at least 6 months after randomization, followed by maintenance with clopidogrel or prasugrel.
Visits scheduled according to treatment duration
Follow-up
Duration - Up to 1 year
Participants are monitored for clinical outcomes including adverse events and cardiovascular events for up to 1 year after treatment initiation.
Periodic visits during the 1 year follow-up
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Optimizing Heart Failure and Chronic Kidney Disease Treatment in Elderly Patients Using Sodium Zirconium Cyclosilicate to Manage Potassium Levels
Long-Term Safety Follow-Up of Participants Previously Treated with Renal Autologous Cell Therapy for Chronic Kidney Disease
Safety Study of Oral Desidustat Over 52 Weeks for Treating Anemia in Adults with Chronic Kidney Disease
Comparing Empagliflozin and Dapagliflozin for Treatment of Type 2 Diabetes, Chronic Kidney Disease, and Heart Failure Using Cluster Randomization in Electronic Health Records
Impact of a 6-Month Home-Based Walking Program on Memory and Brain Health in Older Adults with Chronic Kidney Disease and Mild Cognitive Impairment
Effect of Oral Equol on Vascular Health in Postmenopausal Women With and Without Chronic Kidney Disease
A Randomized, Placebo-Controlled, Crossover Phase 2 Study
Study of Chronic Kidney and Cardiovascular Disease Progression in American Indians of the Southwestern US Using the CRIC Protocols
Study of Colchicine to Treat Heart Disease in Adults with Chronic Kidney Disease Ages 21 to 80
Study of APOL1 Genetic Testing to Understand Kidney Disease Risk and Patient Attitudes in African American Adults
Study Comparing Length of Dual Anti-Platelet Therapy Using Aspirin and Clopidogrel or Prasugrel After New Generation Drug-Eluting Stents in Adults with Advanced Chronic Kidney Disease
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Optimal antiplatelet strategy in patients with advanced chronic kidney disease undergoing drug-eluting stent implantation: Design and rationale of the randomized ADAPT-CKD trial.